These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

77 related articles for article (PubMed ID: 8143564)

  • 21. Venous activated clotting time after intra-arterial heparin: effect of site of administration and timing of sampling.
    Kerensky RA; Azar GJ; Bertolet B; Hill JA; Kutcher MA
    Cathet Cardiovasc Diagn; 1996 Feb; 37(2):151-3. PubMed ID: 8808070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Effect of the nerve growth factor on blood coagulation and fibrinolysis].
    Isanbaev ChI; Vypova NL; Kazantseva DS; Sagdiev N
    Eksp Klin Farmakol; 1997; 60(3):45-7. PubMed ID: 9324398
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [How much does rinsing with heparin influence the analysis of coagulations parameters when bloodletting from one arterial access].
    Janssens U
    Dtsch Med Wochenschr; 1999 Apr; 124(13):405-6. PubMed ID: 10226650
    [No Abstract]   [Full Text] [Related]  

  • 24. In vivo and in vitro evaluation of the heparin management test versus the activated coagulation time for monitoring anticoagulation level in aprotinin-treated patients during cardiac surgery.
    Kim YS; Murkin JM; Adams SJ
    Heart Surg Forum; 2004; 7(6):E599-604. PubMed ID: 15769695
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Parecoxib sodium, an injectable COX-2-specific inhibitor, does not affect unfractionated heparin-regulated blood coagulation parameters.
    Noveck RJ; Hubbard RC
    J Clin Pharmacol; 2004 May; 44(5):474-80. PubMed ID: 15102867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [-Value of activated blood coagulation time in monitoring anticoagulation during coronary angioplasty-].
    Kunert M; Sorgenicht R; Scheuble L; Ketteler T; Lürken E; Meyer I; Müller A; Emmerich K; Gülker H
    Z Kardiol; 1996 Feb; 85(2):118-24. PubMed ID: 8650981
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Antithrombin alfa in hereditary antithrombin deficient patients: A phase 3 study of prophylactic intravenous administration in high risk situations.
    Tiede A; Tait RC; Shaffer DW; Baudo F; Boneu B; Dempfle CE; Horellou MH; Klamroth R; Lazarchick J; Mumford AD; Schulman S; Shiach C; Bonfiglio LJ; Frieling JT; Conard J; von Depka M
    Thromb Haemost; 2008 Mar; 99(3):616-22. PubMed ID: 18327412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monitoring high-dose heparinization during cardiopulmonary by-pass--a comparison between prothrombinase-induced clotting time (PiCT) and two chromogenic anti-factor Xa activity assays.
    Raivio P; Kuitunen A; Petäjä J; Ilveskero S; Lassila R
    Thromb Haemost; 2008 Feb; 99(2):427-34. PubMed ID: 18278195
    [TBL] [Abstract][Full Text] [Related]  

  • 29. When we "act" on ACT levels: activated clotting time measurements to guide heparin administration during and after interventional procedures.
    Klein LW; Agarwal JB
    Cathet Cardiovasc Diagn; 1996 Feb; 37(2):154-7. PubMed ID: 8808071
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of suboptimal concentrations of sodium citrate upon the clotting times of human and dog blood after intravenous administration of heparin.
    LOSNER S; VOLK BW
    Am J Med Sci; 1952 Dec; 224(6):673-8. PubMed ID: 12996513
    [No Abstract]   [Full Text] [Related]  

  • 31. Failure to influence the blood coagulation time by sublingual administration of heparin.
    KENNEDY AC; BROWN A
    Glasgow Med J; 1952 Mar; 33(3):89-91. PubMed ID: 14906847
    [No Abstract]   [Full Text] [Related]  

  • 32. Heparin release is insufficient in syringes with platelets as heparin source.
    Gruber M; Spaeth R; Bechmann V
    Clin Chim Acta; 2008 Sep; 395(1-2):187. PubMed ID: 18515082
    [No Abstract]   [Full Text] [Related]  

  • 33. [Unfractionated standard heparin versus low molecular weight heparins].
    Schrader J; Haas S
    Internist (Berl); 1993 Nov; 34(11):1053-7; discussion 1058. PubMed ID: 8282491
    [No Abstract]   [Full Text] [Related]  

  • 34. A possible interaction between heparin and intravenous nitroglycerin.
    Bushe C; Wales E
    Am J Cardiol; 1991 Jul; 68(2):290. PubMed ID: 1670374
    [No Abstract]   [Full Text] [Related]  

  • 35. Adding intravenous unfractionated heparin to standard enoxaparin causes excessive anticoagulation not detected by activated clotting time: results of the STACK-on to ENOXaparin (STACKENOX) study.
    Drouet L; Bal dit Sollier C; Martin J
    Am Heart J; 2009 Aug; 158(2):177-84. PubMed ID: 19619692
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A train difference in anticoagulant response to subcutaneous administration of heparin in mice.
    Sue TK; Jaques LB; Yelland J
    Thromb Res; 1978 Jan; 12(1):5-13. PubMed ID: 644560
    [No Abstract]   [Full Text] [Related]  

  • 37. The influence of different heparin surface concentrations and antithrombin-binding capacity on inflammation and coagulation.
    Johnell M; Larsson R; Siegbahn A
    Biomaterials; 2005 May; 26(14):1731-9. PubMed ID: 15576147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The monitoring of heparin administration by screening tests in experimental dogs.
    Mischke R; Jacobs C
    Res Vet Sci; 2001 Apr; 70(2):101-8. PubMed ID: 11356088
    [TBL] [Abstract][Full Text] [Related]  

  • 39. How much heparin do we really need to go on pump? A rethink of current practices.
    Shuhaibar MN; Hargrove M; Millat MH; O'Donnell A; Aherne T
    Eur J Cardiothorac Surg; 2004 Nov; 26(5):947-50. PubMed ID: 15519187
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Treatment after myocardial infarction. Is rapid administration of t-PA + heparin most effective?].
    Wirschubsky Z
    Lakartidningen; 1993 Jun; 90(23):2240. PubMed ID: 8502089
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.